|  |
| --- |
|  |

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-Q**

(Mark One)

|  |  |
| --- | --- |
|  | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

For the quarterly period ended **October 31, 2018**

or

|  |  |
| --- | --- |
|  | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

For the transition period from \_\_\_\_\_\_\_\_\_\_\_\_\_ to \_\_\_\_\_\_\_\_\_\_\_\_\_

Commission File Number **333-161157**

|  |
| --- |
| **PIVOT PHARMACEUTICALS INC.** |
| (Exact name of registrant as specified in its charter) |

|  |  |  |
| --- | --- | --- |
| **British Columbia** |   | **N/A** |
| (State or other jurisdiction of incorporation or organization) |   | (IRS Employer Identification No.) |

|  |  |  |
| --- | --- | --- |
| **1275 West 6th Avenue, Vancouver, British Columbia, Canada** |   | **V6H 1A6** |
| (Address of principal executive offices) |   | (Zip Code) |

**(604) 805-7783**

(Registrant’s telephone number, including area code)

**N/A**

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  YES      NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  YES      NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Large accelerated filer |  |   | Accelerated filer |  |
| Non-accelerated filer |  | (Do not check if a smaller reporting company) | Smaller reporting company |  |
|  |  |  | Emerging growth company |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)  YES      NO

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.  YES      NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

96,578,249 common shares issued and outstanding as of December 18, 2018.

|  |
| --- |
|  |

|  |
| --- |
|   |
|   |
|   |
|   |

**TABLE OF CONTENTS**

|  |
| --- |
| [**PART I – FINANCIAL INFORMATION..**](#PART_I_–_FINANCIAL_INFORMATION) |
|  |  |  |   |   |
| [Item 1.](#Item_1._Financial_Statements)  | [Financial Statements.](#Item_1._Financial_Statements) |   | 3 |   |
|  |  |  |   |   |
| [Item 2.](#Item_2._Management’s_Discussion_and_Ana) | [Management’s Discussion and Analysis of Financial Condition and Results of Operations.](#Item_2._Management’s_Discussion_and_Ana) |   | 18 |   |
|  |  |  |   |   |
| [Item 3.](#Item_3._Quantitative_and_Qualitative_Di)  | [Quantitative and Qualitative Disclosure About Market Risk.](#Item_3._Quantitative_and_Qualitative_Di)  |   | 29 |   |
|  |  |  |   |   |
| [Item 4.](#Item_4._Controls_and_Procedures)  | [Controls and Procedures.](#Item_4._Controls_and_Procedures)  |   | 29 |   |
|  |  |  |   |   |
| [**PART II – OTHER INFORMATION..**](#PART_II_–_OTHER_INFORMATION) |
|  |  |  |   |   |
| [Item 1.](#Item_1._Legal_Proceedings)  | [Legal Proceedings.](#Item_1._Legal_Proceedings)  |   | 30 |   |
|  |  |  |   |   |
| [Item 1A.](#Item_1A._Risk_Factors)  | [Risk Factors.](#Item_1A._Risk_Factors)  |   | 30 |   |
|  |  |  |   |   |
| [Item 2.](#Item_2._Unregistered_Sales_of_Equity_Se)  | [Unregistered Sales of Equity Securities and Use of Proceeds.](#Item_2._Unregistered_Sales_of_Equity_Se)  |   | 30 |   |
|  |  |  |   |   |
| [Item 3.](#Item_3._Defaults_Upon_Senior_Securities)  | [Defaults Upon Senior Securities.](#Item_3._Defaults_Upon_Senior_Securities)  |   | 30 |   |
|  |  |  |   |   |
| [Item 4.](#Item_4._Mine_Safety_Disclosures)  | [Mine Safety Disclosures.](#Item_4._Mine_Safety_Disclosures)  |   | 30 |   |
|  |  |  |   |   |
| [Item 5.](#Item_5._Other_Information)  | [Other Information.](#Item_5._Other_Information)  |   | 30 |   |
|  |  |  |   |   |
| [Item 6.](#Item_6._Exhibits) | [Exhibits.](#Item_6._Exhibits) |   | 31 |   |
|  |  |  |   |   |
| [SIGNATURES.](#SIGNATURES)  |  | 34 |   |

|  |
| --- |
|   |
| 2 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PART I – FINANCIAL INFORMATION**

**Item 1. Financial Statements**

Our unaudited interim condensed consolidated financial statements for the period ended October 31, 2018 form part of this quarterly report. All currency references in this report are to U.S. dollars unless otherwise noted. This financial information, in the opinion of management, includes all adjustments consisting of normal recurring entries necessary for the fair presentation of such data. The results of operations for the three and nine month period ended October 31, 2018 are not necessarily indicative of results to be expected for any subsequent period.

|  |
| --- |
|   |
| 3 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Condensed Consolidated Financial Statements

(Expressed in U.S. dollars)

Period ended October 31, 2018 (unaudited) and January 31, 2018

|  |
| --- |
|   |
| 4 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Condensed Consolidated Balance Sheets

(Expressed in U.S. dollars)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **October 31,****2018****$** |  |  | **January 31,****2018****$** |   |
|   |   | **(unaudited)** |   |   |   |   |
| Assets |   |   |   |   |   |   |
| Current assets |   |   |   |   |   |   |
| Cash |   |   | 406,901 |   |   |   | 64,511 |   |
| Prepaid and other current assets |   |   | 142,328 |   |   |   | 84,742 |   |
| Inventory (Note 6) |   |   | 6,795 |   |   |   | – |   |
|   |   |   |   |   |   |   |   |   |
| Total current assets |   |   | 556,024 |   |   |   | 149,253 |   |
|   |   |   |   |   |   |   |   |   |
| Equipment, net (Note 7) |   |   | 3,404 |   |   |   | – |   |
| Intangible assets, net (Notes 3(a), 4 and 8) |   |   | 6,520,449 |   |   |   | 234,564 |   |
|   |   |   |   |   |   |   |   |   |
| Total assets |   |   | 7,079,877 |   |   |   | 383,817 |   |
|   |   |   |   |   |   |   |   |   |
| Liabilities and Stockholders’ Equity (Deficit) |   |   |   |   |   |   |   |   |
| Current liabilities  |   |   |   |   |   |   |   |   |
|   |   |   |   |   |   |   |   |   |
| Accounts payable and accrued liabilities |   |   | 465,410 |   |   |   | 217,921 |   |
| Due to related parties (Note 15) |   |   | 3,255 |   |   |   | 10,104 |   |
| Convertible debenture, net (Note 9) |   |   | 2,722,270 |   |   |   | – |   |
| Promissory note (Note 10) |   |   | – |   |   |   | 201,175 |   |
| Acquisition obligation (Note 4) |   |   | 340,000 |   |   |   | – |   |
| Deferred revenues |   |   | 120,000 |   |   |   | – |   |
| Total current liabilities |   |   | 3,650,935 |   |   |   | 429,200 |   |
| Stockholders’ Equity (Deficit) |   |   |   |   |   |   |   |   |
| Common stock: Unlimited shares authorized, without par value, 95,828,235 and 82,373,559 shares issued and outstanding, respectively (Note 11) |   |   | 16,718,718 |   |   |   | 8,263,767 |   |
| Additional paid-in capital  |   |   | 13,240,333 |   |   |   | 11,816,057 |   |
| Accumulated other comprehensive income  |   |   | 605,199 |   |   |   | 593,728 |   |
| Accumulated deficit  |   |   | (27,135,308 | ) |   |   | (20,718,935 | ) |
| Total stockholders’ equity (deficit) |   |   | 3,428,942 |   |   |   | (45,383 | ) |
| Total liabilities and stockholders’ equity (deficit) |   |   | 7,079,877 |   |   |   | 383,817 |   |

(The accompanying notes are an integral part of these condensed consolidated financial statements)

|  |
| --- |
|   |
| 5 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Condensed Consolidated Statements of Operations and Comprehensive Income

(Expressed in U.S. dollars)

(Unaudited)

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   |   | **Three Months Ended** **October 31,****2018****$** |  |  | **Three Months Ended** **October 31,****2017****$** |  |  | **Nine Months Ended** **October 31,****2018****$** |  |  | **Nine Months Ended** **October 31,****2017****$** |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
| Revenue |   |   | – |   |   |   | – |   |   |   | – |   |   |   | – |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Expenses |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortization (Notes 7 and 8) |   |   | 187,309 |   |   |   | 8,309 |   |   |   | 504,346 |   |   |   | 8,309 |   |
| Due diligence costs |   |   | 52,188 |   |   |   | – |   |   |   | 181,091 |   |   |   | – |   |
| Foreign exchange loss |   |   | 30,702 |   |   |   | 38,762 |   |   |   | 64,789 |   |   |   | 101,324 |   |
| General and administrative |   |   | 432,112 |   |   |   | 50,480 |   |   |   | 1,609,280 |   |   |   | 179,410 |   |
| Licensing fees |   |   | 23,181 |   |   |   | – |   |   |   | 23,181 |   |   |   | – |   |
| Professional fees |   |   | 214,450 |   |   |   | 55,166 |   |   |   | 468,048 |   |   |   | 128,174 |   |
| Rent |   |   | 93,067 |   |   |   | – |   |   |   | 126,690 |   |   |   | – |   |
| Research and development |   |   | 65,029 |   |   |   | – |   |   |   | 237,103 |   |   |   | – |   |
| Salaries and wages |   |   | 313,463 |   |   |   | 31,941 |   |   |   | 817,494 |   |   |   | 301,714 |   |
| Sales and marketing |   |   | 309 |   |   |   | – |   |   |   | 7,309 |   |   |   | – |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Total expenses |   |   | 1,411,810 |   |   |   | 184,658 |   |   |   | 4,039,331 |   |   |   | 718,931 |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Loss from operations |   |   | (1,411,810 | ) |   |   | (184,658 | ) |   |   | (4,039,331 | ) |   |   | (718,931 | ) |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Other income (expense) |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortization of discount/premium on convertible debenture |   |   | (131,772 | ) |   |   | – |   |   |   | (358,467 | ) |   |   | (105,392 | ) |
| Gain on change in fair value of derivative liabilities |   |   | – |   |   |   | 33,260 |   |   |   | – |   |   |   | 204,711 |   |
| Gain on disposal of assets |   |   | – |   |   |   | 609,311 |   |   |   | – |   |   |   | 609,311 |   |
| Gain on repayment of promissory note |   |   | – |   |   |   | – |   |   |   | 6,969 |   |   |   | – |   |
| Gain on settlement of debts |   |   | – |   |   |   | 80,144 |   |   |   | – |   |   |   | 240,144 |   |
| Interest expense |   |   | (134,851 | ) |   |   | (7,331 | ) |   |   | (299,478 | ) |   |   | (24,481 | ) |
| Interest income |   |   | 2,923 |   |   |   | – |   |   |   | 2,923 |   |   |   | – |   |
| Loss on extinguishment of convertible debentures (Note 9) |   |   | (1,508,836 | ) |   |   | – |   |   |   | (1,508,836 | ) |   |   | – |   |
| Other expense |   |   | – |   |   |   | – |   |   |   | (26,967 | ) |   |   | – |   |
| Write-off of deposit (Note 5) |   |   | (193,175 | ) |   |   | – |   |   |   | (193,175 | ) |   |   | – |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Total other income (expense) |   |   | (1,965,711 | ) |   |   | 715,384 |   |   |   | (2,377,031 | ) |   |   | 924,293 |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net (loss) income  |   |   | (3,377,521 | ) |   |   | 530,726 |   |   |   | (6,416,362 | ) |   |   | 205,362 |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Other comprehensive income (loss) |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation adjustment |   |   | 30,639 |   |   |   | (102,502 | ) |   |   | 11,471 |   |   |   | (728 | ) |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net comprehensive loss |   |   | (3,346,882 | ) |   |   | 428,224 |   |   |   | (6,404,891 | ) |   |   | 204,634 |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss per share, basic  |   |   | (0.04 | ) |   |   | 0.01 |   |   |   | (0.07 | ) |   |   | 0.00 |   |
| Net loss per share, diluted |   |   | (0.04 | ) |   |   | 0.01 |   |   |   | (0.07 | ) |   |   | 0.00 |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Weighted average shares outstanding – basic  |   |   | 89,623,532 |   |   |   | 76,761,576 |   |   |   | 88,079,787 |   |   |   | 76,055,298 |   |
| Weighted average shares outstanding –diluted |   |   | 89,632,532 |   |   |   | 81,596,692 |   |   |   | 88,079,787 |   |   |   | 78,877,344 |   |

(The accompanying notes are an integral part of these condensed consolidated financial statements)

|  |
| --- |
|   |
| 6 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Condensed Consolidated Statements of Cash Flows

(Expressed in U.S. dollars)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **Nine Months****Ended****October 31,****2018****$** |  |  | **Nine Months****Ended****October 31,****2017****$** |   |
|   |   | **(unaudited)** |   |   | **(unaudited)** |   |
|   |   |   |   |   |   |   |
| Operating activities |   |   |   |   |   |   |
| Net (loss) income |   |   | (6,416,362 | ) |   |   | 205,362 |   |
| Adjustments to reconcile net loss to net cash used in operating activities: |   |   |   |   |   |   |   |   |
| Amortization of discount/premium on convertible debenture  |   |   | 358,467 |   |   |   | 105,392 |   |
| Depreciation and amortization  |   |   | 504,346 |   |   |   | 8,309 |   |
| Expenses paid related to debt issuance |   |   | (294,221 | ) |   |   | – |   |
| Fair value of stock options vested |   |   | 58,341 |   |   |   | 1,057 |   |
| Gain on change in fair value of derivative liabilities |   |   | – |   |   |   | (204,711 | ) |
| Gain on disposal of assets |   |   | – |   |   |   | (609,311 | ) |
| Gain on repayment of promissory note |   |   | (6,969 | ) |   |   | – |   |
| Gain on settlements of debts |   |   | – |   |   |   | (240,144 | ) |
| Loss on extinguishment of convertible debentures |   |   | 1,508,836 |   |   |   | – |   |
| Stock issued for services |   |   | 443,093 |   |   |   | 24,531 |   |
| Changes in operating assets and liabilities: |   |   |   |   |   |   |   |   |
| Prepaids and other current assets |   |   | (63,691 | ) |   |   | 35,589 |   |
| Inventory |   |   | (6,795 | ) |   |   | – |   |
| Due to related parties |   |   | (6,294 | ) |   |   | 4,510 |   |
| Accounts payable and accrued liabilities |   |   | 240,875 |   |   |   | 457,439 |   |
| Deferred revenue |   |   | 120,000 |   |   |   | – |   |
| Other liabilities |   |   | – |   |   |   | 12,266 |   |
| Net cash used in operating activities  |   |   | (3,560,374 | ) |   |   | (199,711 | ) |
|   |   |   |   |   |   |   |   |   |
| Investing activities |   |   |   |   |   |   |   |   |
| Business acquisition  |   |   | (659,999 | ) |   |   | – |   |
| Net cash used in investing activities  |   |   | (659,999 | ) |   |   | – |   |
|   |   |   |   |   |   |   |   |   |
| Financing activities |   |   |   |   |   |   |   |   |
| Proceeds from convertible debenture, net |   |   | 3,817,119 |   |   |   | – |   |
| Proceeds from debenture |   |   | – |   |   |   | 36,500 |   |
| Proceeds from issuance of common stock |   |   | – |   |   |   | 31,799 |   |
| Proceeds from issuance of common stock subscriptions |   |   | – |   |   |   | 264,326 |   |
| Proceeds from issuance of units |   |   | 976,164 |   |   |   |   |   |
| Proceeds from promissory notes |   |   | 394,616 |   |   |   | – |   |
| Repayment of loan payable |   |   | (15,925 | ) |   |   | – |   |
| Repayment of promissory note |   |   | (588,839 | ) |   |   | – |   |
| Net cash provided by financing activities  |   |   | 4,583,134 |   |   |   | 332,625 |   |
|   |   |   |   |   |   |   |   |   |
| Effects of exchange rate changes on cash  |   |   | (20,371 | ) |   |   | 5,051 |   |
|   |   |   |   |   |   |   |   |   |
| Increase in cash  |   |   | 342,390 |   |   |   | 137,965 |   |
| Cash – beginning of period |   |   | 64,511 |   |   |   | 112,421 |   |
|   |   |   |   |   |   |   |   |   |
| Cash – end of period |   |   | 406,901 |   |   |   | 250,386 |   |

Supplemental cash flow disclosures (Note 14)

(The accompanying notes are an integral part of these condensed consolidated financial statements)

|  |
| --- |
|   |
| 7 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Period ended October 31, 2018

(Expressed in U.S. dollars)

**1. Nature of Operations and Continuance of Business**

Pivot Pharmaceuticals Inc. (the “Company”) was incorporated in British Columbia under the Business Corporations Act on June 10, 2002. On April 7, 2015, the Company changed its name from Neurokine Pharmaceuticals Inc. to Pivot Pharmaceuticals Inc. The Company is in the business of developing and commercializing therapeutic pharmaceuticals and nutraceuticals, as well as drug delivery platform technologies.

These consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at October 31, 2018, the Company has not earned any revenue, has a working capital deficit of $3,094,911 and an accumulated deficit of $27,135,308. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These consolidated financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company be unable to continue as a going concern.

**2. Significant Accounting Policies**

(a) Basis of Presentation

The consolidated financial statements and the related notes of the Company are prepared in accordance with generally accepted accounting principles in the United States and are expressed in U.S. dollars. The Company’s fiscal year-end is January 31.

(b) Use of Estimates

The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets, assumptions used to determine the fair values of stock-based compensation and derivative liabilities and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

(c) Interim Financial Statements

These interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s condensed consolidated financial position, results of operations and cash flows for the periods shown. The condensed consolidated results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. Certain disclosures and financial information have been condensed in accordance with generally accepted accounting principles in the United States.

|  |
| --- |
|   |
| 8 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Period ended October 31, 2018

(Expressed in U.S. dollars)

**2. Significant Accounting Policies** (continued)

These interim consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K (the “2018 Form 10-K”) for the year ended January 31, 2018, which was filed with the Securities and Exchange Commission (the “SEC”) on May 1, 2018.

(d) Basis of Consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company. Control is achieved where the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The consolidating entities include:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **% of ownership** |  |  | **Jurisdiction** |   |
|   |   |  |   |   |   |   |
| Pivot Pharmaceuticals Inc. |   | Parent |   |   | Canada |   |
| Pivot Green Stream Health Solutions Inc. |   |   | 100% |  |   | Canada |   |
| Pivot Naturals, LLC (from date of acquisition on February 28, 2018) |   |   | 100% |  |   | U.S.A. |   |
| Thrudermic, LLC (from date of acquisition on March 2, 2018) |   |   | 100% |  |   | U.S.A. |   |

(e) Loss Per Share

The Company computes net loss per share in accordance with ASC 260, *Earnings Per Share.* ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the consolidated statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. As at October 31, 2018, the Company had 29,776,226 (January 31, 2018 – 6,153,764) potentially dilutive shares.

(f) Financial Instruments and Fair Value Measures

ASC 820, Fair Value Measurements, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1: Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2: Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

|  |
| --- |
|   |
| 9 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Period ended October 31, 2018

(Expressed in U.S. dollars)

**2. Significant Accounting Policies** (continued)

Level 3: Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments consist principally of cash, amounts receivable, accounts payable and accrued liabilities, due to related parties, convertible debenture and promissory note. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

(g) Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial position or results of operations.

**3. Asset Acquisitions**

(a) Thrudermic Transdermal Nanotechnology

On March 2, 2018, the Company entered into an exchange agreement with Thrudermic, LLC (“Thrudermic”) and the members of Thrudermic whereby the Company paid $1.00 for the issued and outstanding units of Thrudermic and issued 500,000 shares of common stock (Notes 8 and 11(b)) to the members of Thrudermic for their intellectual property portfolio, including patents, goodwill and know-how in connection with the Thrudermic Transdermal Nanotechnology.

The Company evaluated this acquisition in accordance with ASC 805, Business Combinations (10-55-4) to discern whether the assets and operations of IndUS met the definition of a business. The Company concluded there were not a sufficient number of key processes obtained to develop the inputs into outputs, nor could such processes be easily obtained by the Company. Accordingly, the Company accounted for this transaction as the acquisition of assets at cost of $805,000 Canadian Dollars ($624,467 US Dollars).

(b) Solumer Oral Drug Delivery Technology

On August 7, 2018, the Company entered into a licensing agreement with Solubest Ltd. (“Solubest”) whereby the Company will acquire worldwide rights for the use, development and commercialization of Solubest’s Solumer Oral Drug Technology solely for the improved bio-availability, delivery and commercialization of Cannabinoid and Tetrahydrocannabinol-based products for human and animal use. Financial considerations include: 1) Monthly license fee until commercialization date ($20,000); 2) Monthly development fee ($10,000); 3) Milestone payments upon commercialization ($150,000) and upon net sales of $5,000,000 ($250,000). Other consideration include royalties on aggregate net sales.

|  |
| --- |
|   |
| 10 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Period ended October 31, 2018

(Expressed in U.S. dollars)

**4. Business Acquisition**   On February 28, 2018, the Company completed the acquisition of Pivot Naturals, LLC (previously ERS Holdings, LLC) (“Pivot Naturals”) pursuant to an exchange agreement dated as of February 10, 2018. As consideration for the purchase, the Company paid $333,333 in cash on closing, issued 5,000,000 shares of common stock (Note 11(a)) and will pay an additional $333,333 six (6) and twelve (12) months after closing. Financial consideration include royalties on future annual net sales. On September 28, 2018, a payment of $326,666, representing a portion of the payment due six (6) months after closing, was made. The remainder of the payment due six (6) months after closing of $6,667 has been withheld due to infringement of the Company’s patent by the recipient. The acquisition obligation outstanding as at October 31, 2018 is $340,000.   The Company evaluated this acquisition in accordance with ASC 805, Business Combinations (10-55-4) to discern whether the assets and operations of Pivot Naturals met the definition of a business. The Company concluded there were a sufficient number of key processes obtained to develop the inputs into outputs and such processes be easily obtained by the Company. Accordingly, the Company accounted for this transaction as an acquisition of a business.

The consideration transferred, assets acquired and liabilities assumed recognized is as follows:

|  |  |  |  |
| --- | --- | --- | --- |
| **Consideration paid:**  |   | **$** |   |
|   |   |   |   |
| Cash paid |   |   | 333,333 |   |
| Cash to be paid |   |   | 666,666 |   |
| Common stock issued |   |   | 5,150,000 |   |
| Total purchase price |   |   | 6,149,999 |   |
|   |   |   |   |   |
| **Net assets acquired:**  |   | **$** |   |
|   |   |   |   |   |
| Cash |   |   | 2,152 |   |
| Equipment |   |   | 4,037 |   |
| Intangible asset (patents) |   |   | 6,190,868 |   |
| Accounts payable and accrued liabilities |   |   | (31,133 | ) |
| Loan payable |   |   | (15,925 | ) |
| Net value of business purchased |   |   | 6,149,999 |   |

The Company applied the acquisition method to the business combination and valued each of the assets acquired (cash, equipment, intangible asset) and liabilities assumed (accounts payable and accrued liabilities and loan payable) at fair value as of the acquisition date. The cash, accounts payable and accrued liabilities and loan payable were deemed to be recorded at fair value as of the acquisition date. The Company determined the fair value of the equipment to be historical net book value. The preliminary allocation of the purchase price was based on estimates of the fair value of the assets and liabilities assumed based on provisional amounts. The allocation of the excess purchase price is not final and the amounts allocated to intangible assets are subject to change pending the completion of final valuations of certain assets and liabilities.

Pursuant to the acquisition, the Company expensed $120,000 of acquisition-related costs. Patents acquired will be amortized over an estimated useful life of ten (10) years.

|  |
| --- |
|   |
| 11 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Period ended October 31, 2018

(Expressed in U.S. dollars)

**5. Deposit**

Pursuant to a letter of intent signed with Agro-Biotech Inc. (“ABI”) on February 19, 2018 for exclusive negotiations related to the acquisition of ABI by April 15, 2018, the Company paid a deposit of $250,000 Canadian Dollars ($196,340 US Dollars). The deposit is non-refundable, except upon wrongful refusal of ABI to conclude the acquisition. The acquisition of ABI was not concluded by April 15, 2018. On April 24, 2018, the Company submitted an originating application to the Superior Court in the province of Quebec, Canada seeking to recover losses arising from the lack of cooperation by ABI, including the deposit made, in concluding the transaction. For the period ended October 31, 2018, the Company wrote-off the balance of the deposit and recorded a loss on write-off of deposit of $193,175.

**6. Inventory**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **October 31,****2018** |  |  | **January 31,****2018** |   |
|   |   |   |   |   |   |   |
| Raw materials |   |   | 6,795 |   |   |   | – |   |

**7. Equipment**

|  |  |  |  |
| --- | --- | --- | --- |
| **Cost**  |   | **Lab****Equipment****$** |   |
|   |   |   |   |
| Balance, January 31, 2018 |   |   | – |   |
| Exchange agreement (Note 4) |   |   | 5,700 |   |
| Balance, October 31, 2018 |   |   | 5,700 |   |

|  |  |  |  |
| --- | --- | --- | --- |
| **Accumulated Amortization**  |   |   |   |
| Balance, January 31, 2018 |   |   | – |   |
| Exchange agreement (Note 4) |   |   | 1,663 |   |
| Amortization |   |   | 633 |   |
|   |   |   |   |   |
| Balance, October 31, 2018 |   |   | 2,296 |   |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Net book value, October 31, 2018 |   |   | 3,404 |   |
| Net book value, January 31, 2018 |   |   | – |   |

|  |
| --- |
|   |
| 12 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Period ended October 31, 2018

(Expressed in U.S. dollars)

**8. Intangible Assets**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cost**  |   | **BiPhasix****License****$** |   |   | **Patents****$** |   |   | **Total****$** |   |
|   |   |   |   |   |   |   |   |   |   |
| Balance, January 31, 2018 |   |   | 259,639 |   |   |   | – |   |   |   | 259,639 |   |
| Addition and exchange agreement (Note 4) |   |   | – |   |   |   | 6,803,408 |   |   |   | 6,803,408 |   |
| Effect of foreign exchange rate changes |   |   | (16,774 | ) |   |   | – |   |   |   | (16,774 | ) |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance, October 31, 2018 |   |   | 242,865 |   |   |   | 6,803,408 |   |   |   | 7,046,273 |   |

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Accumulated Amortization**  |   |   |   |   |   |   |   |   |   |
|   |   |   |   |   |   |   |   |   |   |
| Balance, January 31, 2018 |   |   | 25,075 |   |   |   | – |   |   |   | 25,075 |   |
| Amortization |   |   | 45,413 |   |   |   | 456,667 |   |   |   | 502,080 |   |
| Effect of foreign exchange rate changes |   |   | (1,331 | ) |   |   | – |   |   |   | (1,331 | ) |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance, October 31, 2018 |   |   | 69,157 |   |   |   | 456,667 |   |   |   | 525,824 |   |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net book value, October 31, 2018 |   |   | 173,708 |   |   |   | 6,346,741 |   |   |   | 6,520,449 |   |
| Net book value, January 31, 2018 |   |   | 234,564 |   |   |   | – |   |   |   | 234,564 |   |

**9. Convertible Debenture**

On March 2, 2018, the Company issued convertible debentures with two non-related parties totaling $5,000,000 Canadian Dollars ($3,878,675 US Dollars). The debentures are secured under a General Security Agreement, bear interest at 10% per annum payable quarterly and mature on March 2, 2019. The notes are convertible into common shares at a conversion price equal to $1.74 Canadian Dollars ($1.33 US Dollars) per common share. The Company issued 172,413 share purchase warrants with an exercise price of $1.74 Canadian Dollars and three year expiry as finder’s fee for the convertible debentures.

On October 22, 2018, $1,500,000 Canadian Dollars ($1,144,601 US Dollars) of the convertible debentures were settled through the issuance of 3,750,000 units of the Company with each unit consisting of one common stock and one share purchase warrant with an exercise price of $0.60 Canadian Dollars ($0.46 US Dollars) and three year expiry. The Company considered the settlement to be a substantial modification of the terms of the convertible debenture and recorded a loss on extinguishment of debenture of $1,508,836 in the condensed consolidated statement of operations. Pursuant to the settlement, the Company paid $41,439 representing the remainder of the interest on the debentures settled through maturity date of March 2, 2019.

On October 22, 2018, the Company modified the conversion price on the remainder of the convertible debentures, totaling $3,500,000 Canadian Dollars ($2,670,736 US Dollars), to C$0.42 per common share. As the modification was considered a modification with substantially different terms, the modification has been accounted for as an extinguishment of the original debenture and the recognition of a new convertible debenture with a loss on extinguishment of debenture of $126,327 recorded in the condensed consolidated statement of operations.

As of October 31, 2018, the carrying value of the convertible debenture is $2,722,270, which is inclusive of debt premium of $59,053. As of October 31, 2018, interest accrued on the convertible debenture is $29,725.

|  |
| --- |
|   |
| 13 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Period ended October 31, 2018

(Expressed in U.S. dollars)

**10. Promissory Note**

(a) Promissory Note – Former Chief Executive Officer

The Company issued a promissory note in the amount of $200,000 to its former CEO, which bears interest at 8% per annum. Principal and accrued interest are due on the earlier of: 1) 30 days after the completion of a financing of at least $2,000,000 and (ii) September 10, 2027, provided that if repayment occurs prior to the second anniversary date, all interest will be waived. On March 2, 2018, the Company issued senior secured convertible debentures for gross proceeds of $5,000,000 Canadian dollars (Note 9). Accordingly, accrued interest being waived, principal was due and repaid on March 30, 2018 and a gain on repayment of promissory note of $6,969 was recorded.

(b) Promissory Note – Third Party

On September 27, 2017, the Company issued a promissory note in the amount of $400,000, bearing interest at 12% per annum and maturing on December 31, 2018, which no proceeds have been received by the Company as at October 31, 2018. As part of the promissory note, 100,000 shares of our common stock were issued on October 26, 2017.

(c) Promissory Note – Altum Pharmaceuticals Inc. (“Altum”)

On February 16, 2018, the Company issued a promissory note of up to $560,000 Canadian Dollars ($445,895 US Dollars), bearing interest at 10% per annum to Altum and maturing on May 15, 2018. On February 19 and March 1, 2018, $250,000 Canadian Dollars ($198,981 US Dollars) and $252,464 Canadian Dollars ($196,761 US Dollars) were advanced to the Company. On March 2, 2018, the Company repaid the principal amount and accrued interest on the note totaling $503,285 Canadian Dollars ($390,398 US Dollars).

**11. Common Stock**

|  |  |  |
| --- | --- | --- |
|   | (a) | On February 28, 2018, 5,000,000 shares of common stock, with fair value of $5,191,662, were issued pursuant to the exchange agreement with Pivot Naturals (Note 4). |
|   |   |   |
|   | (b) | On March 2, 2018, 500,000 shares of common stock, with fair value of $620,328, were issued pursuant to the exchange agreement with Thrudermic and the members of Thrudermic (Note 3(a)). |
|   |   |   |
|   | (c) | During the nine months ended October 31, 2018, the Company issued 598,735 shares of common stock, with fair value totaling $323,338, to third parties for services rendered. |
|   |   |   |
|   | (d) | During the nine months ended October 31, 2018 the Company issued 277,691 shares of common stock, with fair value totaling $119,606, as compensation pursuant to employment agreements entered into as part of the acquisitions of the Thrudermic Transdermal Nanotechnology (Note 3(a)) and Pivot Naturals (Note 4). |
|   |   |   |
|   | (e) | On October 22, 2018, 3,750,000 units of the Company, with each unit consisting of one common stock and one share purchase warrant with an exercise price of $0.60 Canadian Dollars and three year expiry, were issued pursuant to settlement of $1,500,000 Canadian Dollars of convertible debentures (Note 9). |

|  |
| --- |
|   |
| 14 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Period ended October 31, 2018

(Expressed in U.S. dollars)

**11. Common Stock** (continued)

|  |  |  |
| --- | --- | --- |
|   | (f) | In October, 2018, 3,328,250 units of the Company, with each unit consisting of one common stock and one share purchase warrant with an exercise price of $0.60 Canadian Dollars and three year expiry, were issued for subscription proceeds of $1,331,300 Canadian Dollars ($1,022,005 US Dollars). Pursuant to the private placement, the Company paid finders’ fee of $64,104 in cash and issued 142,260 share purchase warrants with an exercise price of $0.60 Canadian Dollars and three year expiry. An additional 38,000 share purchase warrants, with an exercise price of $0.60 Canadian Dollars and three year expiry, in finders’ fee were issued on November 2, 2018. |

**12. Stock Options**

Effective December 30, 2015, the Company adopted a stock option plan. Under this plan, the Company may grant options to its directors, officers, employees and consultants up to an amount as determined by the Company and will be no more than a percentage of its outstanding common stock as may be required by the stock exchange the Company is listed with. The exercise price of the stock options will be determined by the Company and will be no less than any minimum exercise price as may be required by the stock exchange the Company is listed with.

The following table summarizes the continuity of the Company’s stock options:

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   |   | **Number****of Options** |   |   | **Weighted** **Average** **Exercise** **Price** **(US$)**  |   |   | **Weighted Average Remaining Contractual Life****(years)** |   |   | **Aggregate****Intrinsic****Value****(US$)** |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
| Outstanding, January 31, 2018 |   |   | 13,620,833 |   |   |   | 0.34 |   |   |   | 3.26 |   |   |   | 22,917,756 |   |
| Granted |   |   | 300,000 |   |   |   | 0.97 |   |   |   | 4.57 |   |   |   | – |   |
| Forfeited |   |   | (229,000 | ) |   |   | (0.26 | ) |   |   | (2.15 | ) |   |   | – |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Outstanding, October 31, 2018  |   |   | 13,691,833 |   |   |   | 0.35 |   |   |   | 2.56 |   |   |   | 1,771,295 |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Exercisable, October 31, 2018  |   |   | 13,475,169 |   |   |   | 0.35 |   |   |   | 2.53 |   |   |   | 1,771,295 |   |

The fair value of stock-based compensation expense was estimated using the Black-Scholes option pricing model and the following assumptions:

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   |   | **Expected Volatility** |   |   | **Risk-free****Interest****Rate** |   |   | **Expected Dividend****Yield** |   |   | **Expected Life****(in years)** |   |
| 100,000 options expiring on November 14, 2022 |   |   | 333 | % |   |   | 2.95 | % |   |   | 0 | % |   |   | 4.04 |   |
| 200,000 options expiring on March 11, 2023 |   |   | 342 | % |   |   | 2.98 | % |   |   | 0 | % |   |   | 4.36 |   |
| 100,000 options expiring on October 28, 2023 |   |   | 364 | % |   |   | 2.98 | % |   |   | 0 | % |   |   | 4.99 |   |

|  |
| --- |
|   |
| 15 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Period ended October 31, 2018

(Expressed in U.S. dollars)

**12. Stock Options** (continued)

Additional information regarding stock options as of October 31, 2018, is as follows:

|  |  |  |  |
| --- | --- | --- | --- |
| **Options Outstanding** |  **Options****Exercisable** | **Exercise****Price****$** | **Expiry Date** |
| 4,000,000 | 4,000,000 | 0.10 | December 14, 2020 |
| 5,250,000 | 5,250,000 | 0.70 | February 22, 2021 |
| 4,000,000 | 4,000,000 | 0.10 | December 14, 2021 |
| 41,833 | 41,833 | 0.05 | January 23, 2022 |
| 100,000 | 50,000 | 0.39 | November 14, 2022 |
| 200,000 | 133,336 | 1.30 | March 11, 2023 |
| 100,000 | - | 0.32 | October 28, 2023 |
| 13,691,833 | 13,475,169 |  |  |

$50,983 of stock-based compensation have yet to be recognized and will be recognized in future periods.

**13. Share Purchase Warrant**

The following table summarizes the continuity of share purchase warrant:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **Number of****Warrants** |   |   | **Weighted Average Exercise Price****$** |   |
|   |   |   |   |   |   |   |
| Balance, January 31, 2018  |   |   | 265,125 |   |   |   | 0.35 |   |
| Granted |   |   | 7,392,923 |   |   |   | 0.48 |   |
| Balance, October 31, 2018 |   |   | 7,658,048 |   |   |   | 0.48 |   |

As at October 31, 2018, the following share purchase warrants were outstanding:

|  |  |  |
| --- | --- | --- |
| **Number of****Warrants**  | **Exercise****Price****$** | **Expiry Date** |
|  |  |   |
| 190,000 | 0.35 | May 20, 2019 |
| 75,125 | 0.35 | June 14 ,2019 |
| 172,413 | 1.35 | March 1, 2021 |
| 2,853,250 | 0.47 | September 21, 2021 |
| 8,000 | 0.47  | October 1, 2021 |
| 609,260 | 0.46  | October 18, 2021 |
| 3,750,000 | 0.46 | October 22, 2021 |
| 7,658,048 |  |  |

|  |
| --- |
|   |
| 16 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PIVOT PHARMACEUTICALS INC.**

Notes to the Condensed Consolidated Financial Statements (Unaudited)

Period ended October 31, 2018

(Expressed in U.S. dollars)

**14. Supplemental Cash Flow Information**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **Nine Months****Ended****October 31,****2018** |   |   | **Nine Months****Ended****October 31,****2017** |   |
| Supplemental disclosures: |   |   |   |   |   |   |
| Interest paid |   |   | 269,293 |   |   |   | – |   |
| Income tax paid |   |   | – |   |   |   | – |   |
| Non-cash investing and financing activities |   |   |   |   |   |   |   |   |
| Capital contribution through forgiveness of debt |   |   | – |   |   |   | 531,310 |   |
| Common stock issued for settlement of accounts payable |   |   | – |   |   |   | 35,152 |   |
| Common stock issued for settlement of convertible debenture (Note 9) |   |   | 1,230,446 |   |   |   | 601,097 |   |
| Common stock issued for prepaid assets |   |   | – |   |   |   | 72,924 |   |
| Common stock issued for intangible asset (Note 3(a)) |   |   | 620,328 |   |   |   | 262,500 |   |
| Common stock issued for services |   |   | 443,093 |   |   |   | 21,207 |   |
| Common stock issued for acquisition of business (Note 4) |   |   | 5,191,662 |   |   |   | – |   |
| Promissory note issued for settlement of accrued salaries |   |   | – |   |   |   | 200,000 |   |
| Treasury stock returned and retired in disposition of assets |   |   | – |   |   |   | 380,000 |   |
| Warrants granted for finder’s fee (Note 9) |   |   | 203,553 |   |   |   | – |   |
| Warrants granted for settlement of convertible debenture (Note 9) |   |   | 1,162,383 |   |   |   | – |   |

**15. Related Party Transactions**

|  |  |  |
| --- | --- | --- |
|   | (a) | As at October 31, 2018, the Company owed $3,255 (January 31, 2018 - $4,767), $1,339 (January 31, 2018 - $nil), $8,270 (January 31, 2018 - $nil) and $1,071 (January 31, 2018 - $nil) to a director, a director and officer, an officer of the Company and an officer of the Company’s subsidiary, respectively, which are unsecured, non-interest bearing, and due on demand. |
|   |   |   |
|   | (b) | On September 12, 2017, the Company entered into a licensing agreement with Altum, a party related by way of common director and officers, whereby the Company acquired worldwide rights to the BiPhasix™ transdermal drug delivery technology for the development and commercialization of Cannabinoids, Cannabidiol and Tetrahydrocannabinol products. |
|   |   |   |
|   | (c) | During the nine months ended October 31, 2018, the Company paid $644 in interest expense on a promissory note issued to Altum (Note 10(c)). |
|   |   |   |
|   | (d) | During the nine months ended October 31, 2018, the Company’s subsidiary, Pivot Naturals, paid $49,540 to a company owned by its President for research and development. |

**16. Subsequent Events**

On November 2, 2018, the Company issued 750,000 units, with each unit consisting of one common stock and one share purchase warrant with an exercise price of $0.60 Canadian Dollars and three year expiry, for subscription proceeds of $300,000 Canadian Dollars. Pursuant to the private placement, the Company paid finders’ fee of $24,000 Canadian Dollars in cash and issued 60,000 share purchase warrants with an exercise price of $0.60 Canadian Dollars and three year expiry. In addition, 38,000 share purchase warrants related to finder’s fee on the private placement in October 2018 were issued (Note 11(f)).

|  |
| --- |
|   |
| 17 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations**

Forward-Looking Statements

This report on Form 10-Q contains certain forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for purposes of these provisions, including any projections of earnings, revenues, or other financial items; any statements of the plans, strategies, and objectives of management for future operation; any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; statements of belief; and any statement of assumptions underlying any of the foregoing. Such forward-looking statements are subject to inherent risks and uncertainties, and actual results could differ materially from those anticipated by the forward-looking statements.

These forward-looking statements involve significant risks and uncertainties, including, but not limited to, the following: competition, promotional costs and the risk of declining revenues. Our actual results could differ materially from those anticipated in such forward-looking statements as a result of a number of factors. These forward-looking statements are made as of the date of this filing, and we assume no obligation to update such forward-looking statements. The following discusses our financial condition and results of operations based upon our unaudited financial statements which have been prepared in conformity with accounting principles generally accepted in the United States. It should be read in conjunction with our financial statements and the notes thereto included elsewhere herein.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are stated in U.S. Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in U.S. Dollars (US$) and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report, the terms “we”, “us”, “our” and “our company” mean Pivot Pharmaceuticals Inc., unless otherwise indicated.

***General Overview***

We are an early stage pharmaceutical company. We were incorporated in the Province of British Columbia, Canada under the name “649186 B.C. Ltd.”, on June 10, 2002. On September 9, 2003, we changed our name to “Xerxes Health Corp.” and on June 26, 2007, we changed our name to “Neurokine Pharmaceuticals Inc.”.

Effective June 4, 2014, we filed with the British Columbia Registrar of Companies a Form 11, Notice of Alteration, wherein we increased our authorized share capital from 500,000,000 common shares without par value to an unlimited number of common shares without par value. The increase of authorized capital was approved by our stockholders at the annual and special meeting held on June 3, 2014.

On September 26, 2014, our company held a special meeting of stockholders to approve the removal of our company’s Pre-Existing Company Provisions, the cancellation of our current Articles and the adoption of new Articles and to approve a reverse stock split on the basis of up to one new common stock for every 100 old common stock.

Effective October 8, 2014, we filed with the British Columbia Registrar of Companies a Form 11, Notice of Alteration, wherein we removed our Pre-Existing Company Provisions.

|  |
| --- |
|   |
| 18 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

Effective April 7, 2015, we filed with the British Columbia Registrar of Companies a Form 11, Notice of Alteration, wherein we changed our name to “Pivot Pharmaceuticals Inc.”.

Effective at the opening of trading on April 20, 2015, as approved by FINRA, our company effected a reverse stock split of our issued and outstanding common shares on the basis of 10 old common stock for 1 new common stock.

On November 20, 2015, we completed the acquisition of IndUS Pharmaceuticals, Inc. (“IndUS”), a Delaware corporation, pursuant to an Agreement and Plan of Merger and Acquisition Agreement dated as of November 4, 2015 among our company, Pivot Pharma U.S. Inc., our wholly owned subsidiary, IndUS and Sindu Research Laboratories Pvt Ltd. As consideration for the purchase, we issued 4,512,500 shares of common stock on November 23, 2015 and 237,500 shares of common stock on December 4, 2015 and granted 41,833 stock options pursuant to the Agreement and Plan of Merger. As part of the acquisition, we appointed Dr. Pravin Chaturvedi as our new Chief Executive Officer and Director. On September 11, 2017, we completed an exchange agreement whereby we exchanged with Dr. Chaturvedi 100% of its shares of common stock of IndUS and IndUS net liabilities for 3,800,000 shares of common stock of Pivot, upon which Dr. Chaturvedi resigned as Chief Executive Officer and Director.

On September 12, 2017, we entered into a licensing agreement with Altum Pharmaceuticals Inc. (“Altum”) whereby we were granted worldwide rights to BiPhasix Transdermal Drug Delivery Technology (“BiPhasix Technology”) for the delivery and commercialization of cannabinoids, cannabidiol (“CBD”), and tetrahydrocannabinol (“THC”) based products. Financial consideration included:

|  |  |  |
| --- | --- | --- |
|   |  | Issuance of 2,500,000 shares of common stock on effective date of agreement |
|   |   |   |
|   |  | Issuance of 2,500,000 shares of common stock of Pivot upon Health Canada Natural Product Number (“NPN”) approval; |
|   |   |   |
|   |  | Royalties on annual gross sales; and |
|   |   |   |
|   |  | For pharmaceutical products, milestone payments payable upon first Investigative New Drug Approval, upon positive outcome of Phase II trial in first indication, and upon New Drug Application approval. |

On September 23, 2017, we entered into a collaboration and license agreement with SolMic GmbH (“Solmic”) whereby we acquired worldwide rights to Solmic’s Solubilisation Technology for the development and commercialization of cannabinoid-containing natural extracts. Milestones include payments upon the following developments: 1) Regulatory approval of a natural health product; 2) First approval of an investigative new drug application for a pharmaceutical product; 3) Positive outcome of a Phase II clinical trial of a pharmaceutical product in the first indication; and 4) Approval of a New Drug Application for a pharmaceutical product by the US Food and Drug Administration. Other consideration include a sales milestone upon aggregate net sales of $5,000,000 and royalties on aggregate net sales.

On December 19, 2017, we commenced trading on the Canadian Securities Exchange under the symbol “PVOT”.

On February 28, 2018, we completed the acquisition of ERS Holdings, LLC (“ERS”) pursuant to an Exchange Agreement dated as of February 10, 2018 among Pivot Pharmaceuticals Inc. (“Pivot”), ERS and the members of ERS. As consideration for the purchase, we paid $333,333 in cash on closing and will pay an additional $333,333 six (6) and twelve (12) months after closing for total cash payment of $1 million. On September 7, 2018, the payment due six (6) months after closing was extended to September 30, 2018. In addition, we also issued 5,000,000 shares of our common stock and will pay royalties on future net sales. ERS has developed a patented technology called “RTIC” Ready-To-Infuse-Cannabis, relating to the transformation of cannabis oil into powder for infusion into a variety of food and beverage products such as capsules, K-Cups, stick packs, baked mixes, liquid shots, protein shakes, topicals, lotions, and bottled beverages.

On March 2, 2018, we completed the acquisition of Thrudermic, LLC (“Thrudermic”) and worldwide rights to Thrudermic’s patented Transdermal Nanotechnology for the development and commercialization of transdermal cannabinoids pursuant to an Exchange Agreement dated as of March 2, 2018 among Pivot, Dr. Joseph Borovsky, Dr. Leonid Lurya and Thrudermic. As consideration for the purchase, we paid $1 in cash on closing and issued 500,000 shares of our common stock.

|  |
| --- |
|   |
| 19 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

On August 7, 2018, we entered into a licensing agreement with Solubest Ltd. (“Solubest”) whereby we acquired worldwide rights for the use, development and commercialization of its patented Solumer™ Oral Drug Delivery Technology (“Solumer™”) for the improved bioavailability, delivery and commercialization of CBD, THC and other biocannabis-based products. Financial consideration included:

|  |  |  |
| --- | --- | --- |
|   |  | Royalties on net sales; |
|   |   |   |
|   |  | Monthly license fee from execution of the agreement until commercialization; |
|   |   |   |
|   |  | Monthly development fee of licensed products; and |
|   |   |   |
|   |  | Milestone payments upon commercialization and aggregate net sales of $5,000,000. |

Our principal executive office is located at 1275 West 6th Avenue, Vancouver, B.C. Canada V6H 1A6. Our telephone number is (604) 805-7783.

***Our Current Business***

We are an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals, as well as drug delivery platform technologies.

Our company focuses on pharmaceutical development of proprietary drug delivery technologies for multiple indications using small molecules, biological and botanical (e.g. cannabinoids) products to treat unmet medical needs. In September 2017, we in-licensed a patented topical transdermal drug delivery technology platform, BiPhasix, and an oral drug delivery technology, Solmic Micelle, for delivery of cannabinoids. We have also acquired the Ready-To-Infuse Cannabis technology in February 2018 and the Thrudermic Transdermal Nanotechnology (transdermal) in March 2018.

Our wholly-owned subsidiaries, Pivot Green Stream Health Solutions Inc. (“PGS”) and Pivot Naturals, LLC (“Pivot Naturals”) (formerly, ERS), focus on the research, development, and commercialization of cannabinoid based nutraceuticals. PGS will generate data to support the safety and efficacy of cannabinoids as Natural Health Product (“NHPs”) as outlined in Health Canada Regulations in order to make particular health claims. Health Canada publishes the Natural Health Products Regulations (“NHPR”) which set out the requirements governing the sale, manufacture, packaging, labelling, importation, distribution and storage of NHPs.

According to Health Canada, the objective of the NHPR is to provide reasonable assurance that products offered for sale in Canada are safe, efficacious and of high quality. PGS may also follow applicable and harmonized regulations for product development and commercialization in the US, European Union and Asia Pacific regions. Alternatively, PGS will commercialize certain cannabinoid products with a Licensed Producer and/or Licensed Distributor as per the regulations concerning Access to Cannabis for Medical Purposes Regulations (“ACMPR”) since certain active ingredients in cannabinoids remain restricted until new legislation permits ease of development and distribution in 2018.

Lastly, PGS may also develop products containing cannabinoid active ingredients obtained from industrial hemp according to the Industrial Hemp Regulations (“IHR”) permitting such products provided they are sourced from industrial hemp. Otherwise stated, this means that the plants and plant parts of the genera Cannabis, the leaves and flowering heads of which do not contain more than 0.3% THC w/w, and includes the derivatives of such plants and plant parts.

PGS’s pipeline targets indications such as cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology and eye disease.

|  |
| --- |
|   |
| 20 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

Our overall strategy includes the following:

|  |  |  |
| --- | --- | --- |
|   | 1. | Acquire market-ready natural health products from third-parties for rebranding and re-sale; |
|   |   |   |
|   | 2. | Acquire cannabinoid-based food additives for medical consumer sales; |
|   |   |   |
|   | 3. | Develop cannabinoid-based natural health products using our BiPhasix topical platform technology; |
|   |   |   |
|   | 4. | Develop pharmaceutical products delivered using our BiPhasix topical platform technology; |
|   |   |   |
|   | 5. | Obtain partnerships with Health Canada approved Authorized Licensed Producers and/or Licensed Distributors, which can provide restricted and non-restricted cannabinoids as per the ACMPR or the IHR; |
|   |   |   |
|   | 6. | Acquire novel proprietary drug delivery technologies, for example, metered dose, intra-nasal, suppositories; |
|   |   |   |
|   | 7. | Make an application at the appropriate time to acquire Health Canada’s Authorized Licensed Producers and Licensed Dealers licenses as per the ACMPR; |
|   |   |   |
|   | 8. | Out-license our platform technologies to Licensed Producers or Licensed Distributors and other drug developers; |
|   |   |   |
|   | 9. | Secure and develop further intellectual property; |
|   |   |   |
|   | 10. | Opportunistically acquire later‑stage drug candidates that provide new treatment options to address unmet medical needs in health care; and |
|   |   |   |
|   | 11. | Establish partnerships with large and specialty pharmaceutical companies and/or biotechnology companies to collaboratively develop and/or commercialize our products. |

***Our Research and Development Strategy***

Our management team has implemented a business minded and cost conscious approach to product research and development by focusing on development of novel therapies to address unmet needs in health care. Our research and development strategy will apply novel drug delivery options for new and/or existing drugs or NHPs.

For a drug to be successful it must be both efficacious and acceptably safe. Before a drug may be commercially marketed, it must be scrutinized and approved by applicable health authorities (such as Health Canada and the FDA in the United States) in each country or jurisdiction where it is sought to be sold. In pharmaceutical research and development, clinical trials are conducted to assess the safety and efficacy of the drug and the data to be collected for such new drugs. Health authorities then scrutinize the preclinical and clinical data and determine, based on the results, whether a drug may be sold to the public. Similarly, clinical trials can only take place once satisfactory information has been gathered on the quality of the product and its non-clinical safety, and approval to conduct clinical trials has been granted by the appropriate health authority in the country where the trial is scheduled to take place.

Clinical trials involving new drugs are commonly classified into four phases. Each phase of the drug approval process is treated as a separate clinical trial. The drug development process will normally proceed through all four phases over many years. If the drug successfully passes through Phases I, II and III, it will usually be approved by the national regulatory authority for use in the general population. Phase IV trials are ‘post approval’ studies. Due to the considerable cost that may be required to complete a full series of clinical trials, the burden of paying for all the necessary people and services is usually borne by the sponsor, who may be the pharmaceutical or biotechnology company that developed the drug that is the subject of the study. Since the diversity of roles may exceed the resources of the sponsor, clinical trials are often managed by outsourced partners such as contract research organizations. Furthermore, approval rates for new drugs at each clinical trial stage are prohibitively low, which may require the sponsor to finance additional trials or abandon the drug under development altogether.

|  |
| --- |
|   |
| 21 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

We will also develop products regulated under Canada’s Natural Health Products Guidance and support claims with clinical based data as per current regulations.

Preclinical safety studies for pharmaceutical or NHP product development will be conducted over the next 12 months to advance at least one of our product candidates.

***Our Platform Technologies***

BiPhasix Transdermal Drug Delivery Technology (Topical Platform)

Pivot has acquired worldwide rights from Altum for its patented topical transdermal drug delivery technology platform, or BiPhasix, which we will use for the delivery and commercialization of cannabinoid, cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) based products.

The BiPhasix technology has the potential to deliver drugs less invasively than by injections. It also has the potential to topically deliver therapeutic amounts of drugs with better absorption rates, where creams, ointments or conventional liposomes have not been effective.

Thrudermic Transdermal Nanotechnology (Topical Platform)

Pivot has acquired the worldwide rights to Thrudermic’s patented Transdermal Nanotechnology for the development and commercialization of transdermal cannabinoids. Developed in Israel, the Thrudermic lipid-based nano dispersion technology for topical cannabinoids uses FDA approved materials. The technology has the ability to specifically formulate individual drugs to control and prolong drug release while maintaining steady therapeutic concentrations, The technology can handle water soluble and water insoluble drugs with no change to the skin morphology, no sensitivity to the digestive system, no pain from injections and no observed adverse reactions.

Solmic Solubilization Drug Delivery Technology (Oral Platform)

Pivot has acquired the worldwide rights to Solmic’s Solubilisation Technology for the development and commercialization of cannabinoid-containing natural extracts. Solmic’s technology allows active ingredients to become water soluble without changing their composition and nature. Solubilized substances that are packed in micelles are protected from degradation from light, stomach acid, and from enzymes released in the intestinal tract. The micellisation process results in a stable, homogenous and transparent mixture, which significantly increases uptake of fat soluble ingredients from the gut into the blood system of fat soluble ingredients, resulting in greater bioavailability.

Solumer Drug Delivery Technology (Oral Platform)

Pivot has acquired the worldwide rights to Solubest’s Solumer Technology for the oral delivery of cannabinoids, such as CBD and THC, with improved bioavailability. The Solumer Technology allows to convert the cannabinoids to powder for tablets and capsules and the powder can be dispersed in liquids to give a clear solution that is colorless, and flavorless for beverage applications.

Ready-To-Infuse Cannabis Technology

Pivot’s patented Ready-To-Infuse-Cannabis (“RTIC”) process technology creates precise and repeatable dosing of cannabis by transforming concentrated cannabis oil into a stable, emulsifiable, odorless and flavorless powder form. The derived powder may then be encapsulated and infused for use in beverages, edibles, lotions and additional health and personal care products. The RTIC process is conducive for manufacturing of a wide array of products, including:

|  |
| --- |
|   |
| 22 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

1. Capsules/Tablets: One of our patents is issued for use in capsules and tablets. Another of our patents has numerous claims for adding other active ingredients to tablets and capsules, such as Melatonin or Gingko Biloba, allowing for specific treatment for targeted effects. Efficient mass production of capsules, conforming to GMP standards is part of our core competencies and manufacturing capabilities. Production of capsules is scheduled for the second quarter of the calendar year 2019.

2. Beverage/Additive Stick Packs: Single-serve stick packs are convenient and functional when used in hot beverages. Stick packs are also highly functional. Production of stick packs is scheduled for the second quarter of the calendar year 2019.

3. Pet Products: Our patented cannabis powder will also be mass produced and packaged in bulk for both consumer pet health needs. Production of pet powders is scheduled for the second quarter of calendar year 2019.

4. Lotions and Topical Creams: Our patented lotion and topical technology will be mass produced and packaged for consumer health needs. Production of lotions and topical creams is scheduled for the first quarter of calendar 2019.

***Our Product Development Initiatives***

Our product development initiatives will address unmet medical needs in health care.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PRODUCT** | **DELIVERY TECHNOLOGY** | **INDICATION** | **GLOBAL MARKET SIZE (1)** | **ESTIMATED PRODUCT LAUNCH** |
| PGS-N001 | Solmic Solubilisate / Oral | Cancer supportive care (CINV) (chemo-induced nausea and vomiting) | >$1B | 2019 |
| PGS-N002 | Solmic Solubilisate / Oral | Restless leg syndrome | >$2B | 2019 |
| PGS-N003 | Solmic Solubilisate / Oral | Pain and inflammation (for opioid withdrawal) | >$15B | 2019 |
| PGS-N004 | Solmic Solubilisate / Oral | Cancer supportive care (mucositis relief) | >$12B | 2019 |
| PGS-N005 | BiPhasix / Topical | Female sexual dysfunction (HSDD) (hypoactive sexual desire disorder) | >$6B | 2019 |
| PGS-N006 | BiPhasix / Topical | Pain and inflammation (joints/opioid withdrawal) | >$20B | 2019 |
| PGS-N007 | BiPhasix / Topical | Dermatology (skin irritation/redness/ itching) | >$13B | 2019 |
| PGS-N008 | BiPhasix / Topical | Eye disease (glaucoma, intra-ocular pressure) | >$3B | 2019 |
| PGS-N009 | Thrudermic / Topical | Pain and inflammation (opioid withdrawal) | >$15B | 2019 |
| PGS-N010 | Solmic Solubilisate / Oral | Migraine (nausea, vomiting, dizziness, sensitivity to light, sounds and smells) | >$10B | 2019 |

\_\_\_\_\_\_\_\_\_\_\_\_

|  |  |
| --- | --- |
| (1) | Derived from IMS data |

***Results of Operations***

The following summary of our results of operations should be read in conjunction with our financial statements for the period ended October 31, 2018, which are included herein.

|  |
| --- |
|   |
| 23 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

Our operating results for the three and nine months ended October 31, 2018 and 2017 are summarized as follows:

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **Three Months Ended** |   |   | **Nine Months Ended**  |   |
|   |   | **October 31,** |   |   | **October 31,** |   |
|   |   | **2018** |   |   | **2017** |   |   | **2018** |   |   | **2017** |   |
| Revenue  |   | $ | Nil |  |   | $ | Nil |   |   | $ | Nil |   |   | $ | Nil |   |
| Amortization  |   | $ | (187,309 | ) |   | $ | (8,309 | ) |   | $ | (504,346 | ) |   | $ | (8,309 | ) |
| Due diligence costs |   | $ | (52,188 | ) |   | $ | Nil |   |   | $ | (181,091 | ) |   | $ | Nil |   |
| Foreign exchange gain (loss)  |   | $ | (30,702 | ) |   | $ | (38,762 | ) |   | $ | (64,789 | ) |   | $ | (101,324 | ) |
| General and administrative  |   | $ | (432,112 | ) |   | $ | (50,480 | ) |   | $ | (1,609,280 | ) |   | $ | (179,410 | ) |
| Licensing fees |   | $ | (23,181 | ) |   | $ | Nil |   |   | $ | (23,181 | ) |   | $ | Nil |   |
| Professional fees  |   | $ | (214,450 | ) |   | $ | (55,166 | ) |   | $ | (468,048 | ) |   | $ | (128,174 | ) |
| Rent |   | $ | (93,067 | ) |   | $ | Nil |   |   | $ | (126,690 | ) |   | $ | Nil |   |
| Research and development |   | $ | (65,029 | ) |   | $ | Nil |   |   | $ | (237,103 | ) |   | $ | Nil |   |
| Salaries and wages |   | $ | (313,463 | ) |   | $ | (31,941 | ) |   | $ | (817,494 | ) |   | $ | (301,714 | ) |
| Sales and marketing |   | $ | (309 | ) |   | $ | Nil |   |   | $ | (7,309 | ) |   | $ | Nil |   |
| Total Other Income (Expenses) |   | $ | (1,965,711 | ) |   | $ | 715,384 |   |   | $ | (2,377,031 | ) |   | $ | 924,293 |   |
| Net Income (Loss)  |   | $ | (3,377,521 | ) |   | $ | 530,726 |   |   | $ | (6,416,362 | ) |   | $ | 205,362 |   |

For the nine months ended October 31, 2018, our net loss increased by $6,621,724 from a net income of $205,362 during the prior period to a net loss of $6,416,362 in the current period. For the three months ended October 31, 2018, our net loss increased by $3,908,247 from a net income of $530,726 during the prior period to a net loss of $3,377,521 in the current period. Net incomes during the three and nine months ended October 31, 2017 resulted primarily from the recognition of gain on settlements of debts related to accrued consulting fees forgiven, debts converted into shares of our common stock, as well as conversion of accrued liabilities related to our past Chief Executive Officer into a promissory note. Net loss increased during the three and nine months ended October 31, 2018 due to the following. In March 2018, our company secured convertible debentures totaling $3,926,804 ($5,000,000 Canadian Dollars), which allowed our company to pursue development of our platform technologies and to secure and develop further intellectual property. During the nine months ended October 31, 2018, we completed the acquisitions of the Thrudermic Transdermal Nanotechnology and Pivot Naturals, LLC and its RTIC patents and performed due diligence on other potential transactions, which resulted in increases to amortization, due diligence costs, consulting fees within general and administrative costs, professional fees and research and development for both the three and nine months ended October 31, 2018. Pursuant to these acquisition, we entered into employment contracts which increased our salaries and wages expense. Should our company be successful in securing continued financing for the development of our platform technologies, we expect our future expenses to be consistent with our expenses for the nine months ended October 31, 2018. In addition to the above increased expenses, we settled convertible debentures totaling $1,144,601 ($1,500,000 Canadian Dollars) through the issuance of 3,750,000 units, with each unit consisting of one common stock and one share purchase warrant, which resulted in a loss on extinguishment of convertible debentures of $1,508,836 being included in other income (expenses).

Revenue

We have not earned any revenues since our inception and we do not anticipate earning revenues in the upcoming quarter.

|  |
| --- |
|   |
| 24 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

***Liquidity and Financial Condition***

Working Capital

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   |   | **At**  |   |   | **At**  |   |
|   |   | **October 31,**  |   |   | **January 31,**  |   |
|   |   | **2018** |   |   | **2018** |   |
| Current Assets  |   | $ |  556,024 |   |   | $ | 149,253 |   |
| Current Liabilities  |   | $ | 3,650,935 |   |   | $ | 429,200 |   |
| Working Capital (Deficit)  |   | $ | (3,094,911 | ) |   | $ | (279,947 | ) |

Our total current assets as of October 31, 2018 were $556,024 as compared to total current assets of $149,253 as of January 31, 2018. The increase was primarily due to cash received upon issuance of convertible debentures of $3,817,119 ($5,000,000 Canadian Dollars) and issuance of units, consisting of a common stock and a share purchase warrant per unit, of $976,164 (net of share issuance costs), offset with cash used for the payments of past obligations, working capital and business acquisitions. Our total current liabilities as of October 31, 2018 were $3,650,935 as compared to total current liabilities of $429,200 as of January 31, 2018. The increase in current liabilities was primarily attributed to convertible debentures of $3,817,119 ($5,000,000 Canadian Dollars) issued during the period and amounts remaining to be paid on the acquisition of Pivot Naturals of $329,419 ($423,923 Canadian Dollars), net of convertible debentures of $1,144,601 ($1,500,000 Canadian Dollars) settled.

Cash Flows

|  |  |  |  |
| --- | --- | --- | --- |
|   |   | **Nine Months Ended**  |   |
|   |   | **October 31,** |   |
|   |   | **2018** |   |   | **2017** |   |
| Net Cash Used In Operating Activities  |   | $ | (3,560,374 | ) |   | $ | (199,711 | ) |
| Net Cash Used In Investing Activities |   | $ | (659,999 | ) |   | $ | Nil |   |
| Net Cash Provided By Financing Activities  |   | $ | 4,583,134 |   |   | $ | 332,625 |   |
| Effects of Exchange Rate Changes on Cash |   | $ | (20,371 | ) |   | $ | 5,051 |   |
| **Increase (Decrease) in Cash During the Period**  |   | **$** | **342,390** |  |   | **$** | **137,965** |  |

*Operating Activities*

During the nine months ended October 31, 2018, our cash used by operating activities increased by $3,360,663 when compared to cash used in operating activities during the nine months ended October 31, 2017. During the period, we acquired Pivot Naturals and the Thrudermic Transdermal Nanotechnology, which resulted in increase in due diligence costs, general and administration, professional fees and salaries and wages. In addition, proceeds from convertible debentures issued during the period allowed our company to pursue our business strategy, including development of our oral and transdermal drug delivery platforms and preparation of our RTIC products for production and commercialization, which resulted in increased research and development costs and rent from securing manufacturing facilities.

*Investing Activities*

During the nine months ended October 31, 2018, we acquired Pivot Naturals through the issuance of 5,000,000 shares of our common stock and a payment of $659,999. We did not have any investing activities during the nine months ended October 31, 2017.

*Financing Activities*

During the nine months ended October 31, 2018, we received net proceeds of $3,817,119 from convertible debentures, $394,616 from promissory note and $976,164 from issuance of units of our company. We repaid loan payable and promissory notes of $15,925 and $588,839, respectively.

|  |
| --- |
|   |
| 25 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

We will require additional funds to fund our budgeted expenses over the next 12 months. These funds may be raised through equity financing, debt financing, or other sources, which may result in further dilution in the equity ownership of our shares. There is still no assurance that we will be able to maintain operations at a level sufficient for an investor to obtain a return on his investment in our common stock. Further, we may continue to be unprofitable. We need to raise additional funds in the immediate future in order to proceed with our budgeted expenses.

Specifically, we estimate our expenses and working capital requirements for the next 12 months to be as follows:

|  |  |  |  |
| --- | --- | --- | --- |
| **Product Development** |   | **Estimated Expenses** |   |
| Development of BiPhasix Topical Cream (20g) |   | $ | 1,430,000 |   |
| Development of Thrudermic Topical Tube (20g) |   |   | 1,590,000 |   |
| Development of Solmic Oral Dropper Bottle (30ml) |   |   | 1,040,000 |   |
| Development of Ready-to-infuse Powderized Products |   |   | 2,310,000 |   |
| Product Registration and Regulatory |   |   | 1,590,000 |   |
| Data Generation to Claim Indications |   |   | 3,180,000 |   |
| Manufacturing and Supply |   |   | 7,150,000 |   |
| **Sales and Marketing Costs**  |   |  | **3,970,000** |  |
| **General and Administrative**  |   |  | **1,990,000** |  |
| **Total:** |   | **$** | **24,250,000** |  |

Based on our planned expenditures, we will require additional funds of approximately $24.25 million to proceed with our business plan over the next 12 months and the commencement of commercialization of our product initiatives. If we secure less than the full amount of financing that we require, we will not be able to carry out our complete business plan and we will be forced to proceed with a scaled back business plan based on our available financial resources.

Funds raised will be used towards the recruitment of appropriate management and research and development (“R&D”) personnel, as well as towards product development expenditures. Specifically, the funds will be used to cover R&D expenses associated with 1) manufacturing scale-up of our products at a GMP-certified, high potency drug manufacturing facility; 2) development and manufacture of formulation of our products at a GMP-certified product manufacturing facility for administration of the drug candidates in animals (for safety evaluation) and subsequently to humans 3) submission to appropriate regulatory authorities for NHP registration.

We anticipate that we will incur substantial losses for the foreseeable future. We have negative cash flows from current operating activities and may continue to be unprofitable. Even if we carry out our expanded research and development activities on our products, there is no guarantee that we will be able to market them or derive any revenues from their sale.

|  |
| --- |
|   |
| 26 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

Although we are anticipating commercialization to commence on some of our product initiatives over the next 12 months, anticipated revenues will not be sufficient to finance our business plan. We intend to raise capital through equity and, if necessary, debt financing. We anticipate that the bulk of any additional funding we receive will be in the form of equity financing from the sale of our common stock. However, we do not have any financing arranged and we cannot provide any assurance that we will be able to raise sufficient funds from the sale of our common stock to fund our operations or planned research and development activities. In the absence of such financing, we will not be able to carry out our planned research and development activities. Even if we are successful in obtaining equity financing to fund our operations and research and development activities, there is no assurance that we will obtain the funding necessary to pursue any advanced research and development following the completion of our planned clinical trials. If we do not continue to obtain additional financing, we may be forced to abandon our business plan. There is no assurance that we will be able to maintain operations at a level sufficient for an investor to obtain a return on his investment in our common stock.

Any modifications to our plans will be based on many factors, including the results of our R&D and the amount of available capital. Further, the extent to which we carry out our development of planned products is dependent upon the amount of financing available to us.

**Future Financings**

We will require additional financing in order to enable us to proceed with our plan of operations, as discussed above, including approximately $24.25 million over the next 12 months to pay for product development, sales and marketing and general and administrative expenses. These cash requirements are in excess of our current cash and working capital resources. Accordingly, we will require additional financing in order to continue operations and to repay our liabilities. There is no assurance that any party will advance additional funds to us in order to enable us to sustain our plan of operations or to repay our liabilities.

We anticipate continuing to rely on equity sales of our common stock in order to continue to fund our business operations. Issuances of additional shares will result in dilution to our existing stockholders. There is no assurance that we will achieve any additional sales of our equity securities or arrange for debt or other financing to fund our planned business activities.

We presently do not have any arrangements for additional financing for the expansion of our operations, and no potential lines of credit or sources of financing are currently available for the purpose of proceeding with our plan of operations.

**Inflation**

The amounts presented in the consolidated financial statements do not provide for the effect of inflation on our operations or financial position. The net operating losses shown would be greater than reported if the effects of inflation were reflected either by charging operations with amounts that represent replacement costs or by using other inflation adjustments.

**Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

**Critical Accounting Policies**

The discussion and analysis of our consolidated financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our consolidated financial statements is critical to an understanding of our consolidated financial statements.

|  |
| --- |
|   |
| 27 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

*Use of Estimates*

The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Our company regularly evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets, assumptions used to determine the fair values of stock-based compensation and derivative liabilities, and deferred income tax asset valuation allowances. Our company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by our company may differ materially and adversely from our company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

*Long-lived Assets*

In accordance with ASC 360, “Property, Plant and Equipment”, our company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

*Stock-Based Compensation*

Our company records stock-based compensation in accordance with ASC 718, *Compensation – Stock-Based Compensation*, using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

*Financial Instruments and Fair Value Measures*

ASC 820, *Fair Value Measurements*, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

*Level 1 -* Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

*Level 2 -* Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

*Level 3 -* Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

|  |
| --- |
|   |
| 28 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

Our company’s financial instruments consist principally of cash, accounts payable and accrued liabilities and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets and derivative liabilities is determined based on “Level 2” inputs, as determined by observable market data. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

*Foreign Currency Translation*

The functional currency of our parent entity, Pivot Pharmaceuticals Inc., and our wholly-owned subsidiary, Pivot Green Stream Health Solutions Inc., is the Canadian dollar. The functional currency of our wholly-owned subsidiary, Pivot Naturals, LLC, is the US dollar. Our company’s presentation currency is the US dollar.

Monetary assets and liabilities are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Expenses are translated at average rates for the period. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income.

Results of operations are translated into our company’s presentation currency, US dollars, at an appropriate average rate of exchange during the year. Net assets and liabilities are translated to US dollars for presentation purposes at rates of exchange in effect at the end of the period. Gains or losses arising on translation are recognized in other comprehensive income (loss) as foreign currency translation adjustments.

*Recent Accounting Pronouncements*

Our company has implemented all new accounting pronouncements that are in effect and that may impact our consolidated financial statements and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our consolidated financial position or results of operations.

**Item 3. Quantitative and Qualitative Disclosure About Market Risk**

As a “smaller reporting company”, we are not required to provide the information required by this Item.

**Item 4. Controls and Procedures**

*Evaluation of Disclosure Controls and Procedures*

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer (our principal executive officer) and our chief financial officer (principal financial officer and principal accounting officer), as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer (our principal executive officer) and our chief financial officer (principal financial officer and principal accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures as of quarter covered by this report. Based on the evaluation of these disclosure controls and procedures our chief executive officer (our principal executive officer) and our chief financial officer (principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures were not effective.

*Changes in Internal Controls*

During the quarter covered by this report there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

|  |
| --- |
|   |
| 29 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**PART II – OTHER INFORMATION**

**Item 1. Legal Proceedings**

We know of no material, existing or pending legal proceedings against us. On April 24, 2018, we submitted an originating application to the Superior Court in the province of Quebec, Canada seeking to recover losses arising from the lack of cooperation by Agro-Biotech Inc. in negotiating a contemplated acquisition. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

**Item 1A. Risk Factors**

As a “small reporting company”, we are not required to provide the information required by this Item.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

None.

|  |
| --- |
|   |
| 30 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**Item 6. Exhibits**

|  |  |  |
| --- | --- | --- |
|  **Exhibit Number** |   |  **Description** |
| **(3)** |   | **Articles of Incorporation and Bylaws**  |
| [3.1](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-1.htm) |   | [Articles of Incorporation 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-1.htm)  |
| [3.2](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-2.htm) |   | [“Company Act” Memorandum of 649186 B.C. Ltd. Certificate of Amendment (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-2.htm)  |
| [3.3](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-3.htm) |   | [Certificate of Filing of 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-3.htm)  |
| [3.4](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-4.htm) |   | [Certificate of Incorporation of 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-4.htm)  |
| [3.5](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-5.htm) |   | [Certificate of Name Change of 649186 B.C. Ltd. to Xerxes Health Corp. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-5.htm)  |
| [3.6](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-6.htm) |   | [Transition Application of Xerxes Health Corp. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-6.htm)  |
| [3.7](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-7.htm) |   | [Certificate of Name Change of Xerxes Health Corp. to Neurokine Pharmaceuticals Inc. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-7.htm)  |
| [3.8](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-8.htm) |   | [Notice of Alteration to Authorized Share Structure (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000329/ex3-8.htm)  |
| [3.9](http://www.sec.gov/Archives/edgar/data/1464165/000151116414000332/exhibit31noticeofalteration.htm) |   | [Notice of Alteration to Authorized Share Structure (incorporated by reference from our Current Report on Form 8-K filed on June 4, 2014)](http://www.sec.gov/Archives/edgar/data/1464165/000151116414000332/exhibit31noticeofalteration.htm) |
| [3.10](http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_31.htm) |   | [Form 11 Notice of Alteration (incorporated by reference from our Current Report on Form 8-K filed on October 9, 2014)](http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_31.htm) |
| [3.11](http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_32.htm) |   | [Articles (incorporated by reference from our Current Report on Form 8-K filed on October 9, 2014)](http://www.sec.gov/Archives/edgar/data/1464165/000147793214005324/neukf_32.htm) |
| [3.12](http://www.sec.gov/Archives/edgar/data/1464165/000147793215002579/neukf_ex31.htm) |  | [Notice of Alteration changing name to Pivot Pharmaceuticals Inc. (incorporated by reference to our Current Report on Form 8-K filed on April 17, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215002579/neukf_ex31.htm) |
| [3.13](http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex313.htm) |  | [Certificate of Name Change of Neurokine Pharmaceuticals Inc. to Pivot Pharmaceuticals Inc. (filed on June 17, 2015 with our Annual Report on Form 10K/A)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex313.htm) |
| **(10)** |   | **Material Contracts**  |  |
| [10.1](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-2.htm) |   | [Non-Exclusive License Agreement with Globe Laboratories Inc. dated June 17, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-2.htm)  |  |
| [10.2](http://www.sec.gov/Archives/edgar/data/1464165/000141540810000078/ex10-8.htm) |   | [Clinical Trial Services Agreement with Virtus Clinical Development (Pty) Limited dated March 1, 2009 (incorporated by reference to our Registration Statement on Form S-1/A filed on March 4, 2010)](http://www.sec.gov/Archives/edgar/data/1464165/000141540810000078/ex10-8.htm)  |  |
| [10.3](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-9.htm) |   | [Master Service Agreement with Northern Lipids Inc. dated October 2, 2007 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-9.htm)  |  |
| [10.4](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-10.htm) |   | [Assignment of Invention (NK-001) dated January 30, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-10.htm)  |  |
| [10.5](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-11.htm) |   | [Assignment of Invention (NK-002) dated April 18, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)](http://www.sec.gov/Archives/edgar/data/1464165/000141540809000540/ex10-11.htm)  |  |

|  |
| --- |
|   |
| 31 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

|  |  |  |
| --- | --- | --- |
| [10.6](http://www.sec.gov/Archives/edgar/data/1464165/000106299310002584/exhibit10-2.htm) |  | [Subscription Agreement with Ahmad Doroudian (incorporated by reference to our Form 8-K filed on August 12, 2010)](http://www.sec.gov/Archives/edgar/data/1464165/000106299310002584/exhibit10-2.htm)  |
| [10.7](http://www.sec.gov/Archives/edgar/data/1464165/000151116413000559/neurokineadoroudiandebtsettl.htm) |  | [Debt Settlement Subscription Agreement dated September 26, 2013 with Ahmad Doroudian (incorporated by reference to our Quarterly Report on Form 10-Q filed on December 16, 2013)](http://www.sec.gov/Archives/edgar/data/1464165/000151116413000559/neurokineadoroudiandebtsettl.htm) |
| [10.8](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_101.htm) |  | [Director Services Agreement dated February 25, 2015 with Barbara-Jean Bormann-Kennedy (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_101.htm) |
| [10.9](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_103.htm) |  | [Director Services Agreement dated February 25, 2015 with Dr. Patrick Frankham (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_103.htm) |
| [10.10](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_102.htm) |  | [Director Services Agreement dated February 26, 2015 with Dr. Wolfgang Renz (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_102.htm) |
| [10.11](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_104.htm) |  | [Consulting Services Agreement dated February 25, 2015 with Dr. Giora Davidai (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215001920/neukf_104.htm) |
| [10.12](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1012.htm) |  | [Director Services Agreement dated November 19, 2015 with Dr. Patrick Frankham (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1012.htm) |
| [10.13](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1013.htm) |  | [Director Services Agreement dated November 19, 2015 with Dr. Wolfgang Renz (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1013.htm) |
| [10.14](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1014.htm) |  | [Consulting Services Agreement dated November 19, 2015 with Dr. Giora Davidai (incorporated by reference to our Quarterly Report on Form 10‑Q filed on December 15, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1014.htm) |
| [10.15](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007334/pvotf_ex101.htm) |  | [Plan of Merger and Acquisition Agreement between our company and IndUS Pharmaceuticals, Inc., dated November 4, 2015 (incorporated by reference to our Current Report on Form 8‑K filed on November 23, 2015 and our Current Report on Form 8‑K/A filed on February 3, 2016)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007334/pvotf_ex101.htm) |
| [10.16](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1016.htm) |  | [Employment Agreement dated November 20, 2015 with Dr. Pravin Chaturvedi (incorporated by reference to our Quarterly Report on Form 10‑Q filed on December 15, 2015)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007631/pvotf_ex1016.htm) |
| [10.17](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1017.htm) |  | [Employment Agreement dated February 1, 2016 with Dr. Ahmad Doroudian (filed on April 29, 2016 with our Annual Report on Form 10-K)](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1017.htm) |
| [10.18](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1018.htm) |  | [Employment Agreement dated February 1, 2016 with Moira Ong (filed on April 29, 2016 with our Annual Report on Form 10-K)](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1018.htm) |
| [10.19](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1019.htm) |  | [Consulting Services Agreement dated February 1, 2016 with Soho Capital Inc. (filed on April 29, 2016 with our Annual Report on Form 10-K)](http://www.sec.gov/Archives/edgar/data/1464165/000147793216009996/pvotf_ex1019.htm) |
| [10.20](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1020.htm) |  | [Convertible debenture agreement dated September 29, 2016 with Avro Capital Partners Inc. (incorporated by reference to our Quarterly Report on Form 10-Q filed on September 14, 2017)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1020.htm) |
| [10.21](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1021.htm) |  | [Exchange Agreement between our company, IndUS Pharmaceuticals, Inc. and Pravin Chaturvedi, dated September 11, 2017 (incorporated by reference to our Current Report on Form 8-K filed on September 12, 2017)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1021.htm) |
| [10.22](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1022.htm) |  | [Licensing Agreement between our company and Altum Pharmaceuticals Inc. dated September 12, 2017 (incorporated by reference to our Current Report on Form 8-K filed on September 12, 2017)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004439/pvotf_ex1022.htm) |
| [10.23](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1023.htm) |  | [Debt Forgiveness Agreement dated July 31, 2017 between our company and Dr. Ahmad Doroudian (filed on September 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1023.htm) |
| [10.24](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1024.htm) |  | [Debt Forgiveness Agreement dated July 31, 2017 between our company and Moira Ong (filed on September 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1024.htm) |

|  |
| --- |
|   |
| 32 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

|  |  |  |
| --- | --- | --- |
| [10.25](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1025.htm) |   | [Debt Forgiveness Agreement dated July 31, 2017 between our company and Soho Capital Inc. (filed on September 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217004528/pvotf_ex1025.htm) |
| [10.26](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1026.htm) |   | [Debt Settlement Agreement dated September 18, 2017 between our company and Avro Capital Partners, Inc. (filed on December 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1026.htm) |
| [10.27](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1027.htm) |   | [Collaboration and License Agreement dated September 23, 2017 between our company and SolMic GmbH (filed on December 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1027.htm) |
| [10.28](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1028.htm) |   | [Letter of Intent dated November 7, 2017 between our company and Thrudermic LLC (filed on December 15, 2017 with our Quarterly Report on Form 10-Q)](http://www.sec.gov/Archives/edgar/data/1464165/000147793217006095/pvotf_ex1028.htm) |
| [10.29](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1029.htm) |   | [Share Exchange Agreement between our company, ERS Holdings, LLC and the members of ERS Holdings, LLC dated February 10, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1029.htm) |
| [10.30](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1030.htm) |   | [Royalty Agreement between our company and AquaBrew Inc. dated March 1, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1030.htm) |
| [10.31](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1031.htm) |   | [Employment Agreement between our company and Patrick Rolfes dated March 1, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1031.htm) |
| [10.32](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1032.htm) |   | [Share Exchange Agreement between our company, Thrudermic, LLC, Dr. Joseph Borovsky and Dr. Leonid Lurya dated March 2, 3018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1032.htm) |
| [10.33](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1033.htm) |   | [Employment Agreement between our company and Joseph Borovsky dated March 1, 2018 (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1033.htm) |
| [10.34](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1034.htm) |   | [10% Senior Secured Convertible Debenture (CDN$2,500,000) due March 2, 2019 (CD-1) (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1034.htm) |
| [10.35](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1035.htm) |   | [10% Senior Secured Convertible Debenture (CDN$2,500,000) due March 2, 2019 (CD-2) (incorporated by reference to our Current Report on Form 8-K filed on March 12, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218001207/pvotf_ex1035.htm) |
| [10.36](http://www.sec.gov/Archives/edgar/data/1464165/000147793218005263/pvotf_ex1036.htm) |   | [10% Senior Secured Convertible Debenture (CDN$1,750,000) due March 2, 2019 (CD-3) (incorporated by reference to our Current report on Form 8-K filed on November 6, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218005263/pvotf_ex1036.htm) |  |  |
| [10.37](http://www.sec.gov/Archives/edgar/data/1464165/000147793218005263/pvotf_ex1037.htm) |   | [10% Senior Secured Convertible Debenture (CDN$1,750,000) due March 2, 2019 (CD-4) (incorporated by reference to our Current report on Form 8-K filed on November 6, 2018)](http://www.sec.gov/Archives/edgar/data/1464165/000147793218005263/pvotf_ex1037.htm) |  |  |
| **(31)** |   | **Rule 13a-14(d)/15d-14(d) Certifications**  |  |  |
| [31.1\*](file:///C%3A%5Cedger%5Cpvotf_ex311.htm) |   | [Section 302 Certification under the Sarbanes-Oxley Act of 2002 of Principal Executive Officer](file:///C%3A%5Cedger%5Cpvotf_ex311.htm) |  |  |
| [31.2\*](file:///C%3A%5Cedger%5Cpvotf_ex312.htm) |   | [Section 302 Certification under the Sarbanes-Oxley Act of 2002 of Principal Financial Officer](file:///C%3A%5Cedger%5Cpvotf_ex312.htm) |  |  |
| **(32)** |   | **Section 1350 Certifications**  |  |  |
| [32.1\*](file:///C%3A%5Cedger%5Cpvotf_ex321.htm) |   | [Section 906 Certification under the Sarbanes-Oxley Act of 2002 of Principal Executive Officer](file:///C%3A%5Cedger%5Cpvotf_ex321.htm) |  |  |
| [32.2\*](file:///C%3A%5Cedger%5Cpvotf_ex322.htm) |   | [Section 906 Certification under the Sarbanes-Oxley Act of 2002 of Principal Financial Officer](file:///C%3A%5Cedger%5Cpvotf_ex322.htm) |  |  |
| **99** |  | **Additional Exhibits** |
| [99.1](http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex991.htm) |  | [Audit Committee Charter (filed on June 17, 2015 with our Annual Report on Form 10K/A)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215003905/pvotf_ex991.htm) |  |
| [99.2](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007379/pvotf_def14a.htm) |  | [Stock Option Plan (filed on November 25, 2015 with our Definitive Proxy Statement on Schedule 14A)](http://www.sec.gov/Archives/edgar/data/1464165/000147793215007379/pvotf_def14a.htm) |  |
| **101\*** |   | **Interactive Data Files** |  |  |  |
| 101.INS |   | XBRL Instance Document |  |  |  |
| 101.SCH |   | XBRL Taxonomy Extension Schema Document |  |  |  |
| 101.CAL |   | XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |
| 101.DEF |   | XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |
| 101.LAB |   | XBRL Taxonomy Extension Label Linkbase Document |  |  |  |
| 101.PRE |   | XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |

*\_\_\_\_\_\_\_\_\_\_\_\_*

|  |  |
| --- | --- |
| \* | Filed herewith |

|  |
| --- |
|   |
| 33 |
|   |
| [*Table of Contents*](#TABLE_OF_CONTENTS) |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

|  |  |  |  |
| --- | --- | --- | --- |
|  |   |  |   |
|  |   | **PIVOT PHARMACEUTICALS INC.**  |   |
|  |   | (Registrant)  |   |
|   |   |   |   |
| Dated: December 18, 2018 |   | */s/ Patrick Frankham* |   |
|  |   | **Dr. Patrick Frankham**  |   |
|  |   | Chief Executive Officer and Director |   |
|  |   | (Principal Executive Officer)  |   |
|   |   |   |   |
| Dated: December 18, 2018 |   | */s/ Moira Ong* |   |
|  |   | **Moira Ong**  |   |
|  |   | Chief Financial Officer  |   |
|  |   | (Principal Financial Officer and Principal Accounting Officer) |   |

|  |
| --- |
| 34 |

**EXHIBIT 31.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Patrick Frankham, certify that:

|  |  |
| --- | --- |
| 1. | I have reviewed this quarterly report on Form 10-Q of Pivot Pharmaceuticals Inc.; |
|   |   |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|   |   |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|   |   |
| 4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |

|  |  |  |
| --- | --- | --- |
|   | (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|   |   |   |
|   | (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|   |   |   |
|   | (c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|   |   |   |
|   | (d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |

|  |  |
| --- | --- |
| 5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |

|  |  |  |
| --- | --- | --- |
|   | (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|   |   |   |
|   | (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |

Date: December 18, 2018

|  |  |
| --- | --- |
| */s/ Patrick Frankham* |   |
| Patrick Frankham |   |
| Chief Executive Officer and Director(Principal Executive Officer) |   |

**EXHIBIT 31.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Moira Ong, certify that:

|  |  |
| --- | --- |
| 1. | I have reviewed this quarterly report on Form 10-Q of Pivot Pharmaceuticals Inc.; |
|   |   |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|   |   |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|   |   |
| 4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |

|  |  |  |
| --- | --- | --- |
|   | (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|   |   |   |
|   | (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|   |   |   |
|   | (c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|   |   |   |
|   | (d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |

|  |  |
| --- | --- |
| 5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |

|  |  |  |
| --- | --- | --- |
|   | (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|   |   |   |
|   | (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |

Date: December 18, 2018

|  |  |
| --- | --- |
| */s/ Moira Ong* |   |
| Moira Ong |   |
| Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |   |

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Patrick Frankham, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

|  |  |
| --- | --- |
| (1) | the Quarterly Report on Form 10-Q of Pivot Pharmaceuticals Inc. for the period ended October 31, 2018 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|   |   |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Pivot Pharmaceuticals Inc. |

|  |  |  |  |
| --- | --- | --- | --- |
|   |  |  |  |
| Dated: December 18, 2018 |   | */s/ Patrick Frankham* |  |  |
|  |   | Patrick Frankham |  |
|  |   | Chief Executive Officer and Director (Principal Executive Officer) |  |
|  |   | Pivot Pharmaceuticals Inc.  |  |

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Pivot Pharmaceuticals Inc. and will be retained by Pivot Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

**EXHIBIT 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Moira Ong, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

|  |  |
| --- | --- |
| (1) | the Quarterly Report on Form 10-Q of Pivot Pharmaceuticals Inc. for the period ended October 31, 2018 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|   |   |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Pivot Pharmaceuticals Inc. |

|  |  |  |  |
| --- | --- | --- | --- |
|   |  |  |  |
| Dated: December 18, 2018 |   | */s/ Moira Ong* |  |  |
|  |   | Moira Ong |  |
|  |   | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |  |
|  |   | Pivot Pharmaceuticals Inc. |  |

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Pivot Pharmaceuticals Inc. and will be retained by Pivot Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.